Davis Polk advised the representatives of the underwriters in connection with the offering of $5.0 billion aggregate principal amount of notes issued by Merck & Co., Inc. The notes were offered in four tranches, maturing in 2024, 2029, 2039 and 2049.
Goldman Sachs & Co. LLC, J.P. Morgan, Morgan Stanley, Citigroup, Credit Suisse, Mizuho Securities, BBVA, HSBC, Santander, SMBC Nikko, US Bancorp, Wells Fargo Securities, Academy Securities and Blaylock Van, LLC acted as underwriters on the deal.
Merck is a global healthcare leader that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products.
The Davis Polk capital markets team included partner Byron B. Rooney and associate Heita Miki. The tax team included partner Lucy W. Farr and associate Ben Levenback.
Law Firms: Davis Polk & Wardwell;
Clients: Academy Securities; BBVA Bancomer; Blaylock Van, LLC; Citigroup Inc.; Credit Suisse; Goldman Sachs & Co.; Hsbc Bank plc; JP Morgan; Mizuho Securities; Morgan Stanley; Santander Consumer Bank AG; Smbc Nikko Capital Markets Limited; US Bancorp; Wells Fargo Securities;